Navigation Links
LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
Date:2/1/2010

rious adverse events reported. The trials were initiated and run by Peplin, Inc., acquired by LEO Pharma in September 2009.  

Results from REGION I and Ib will be presented at an upcoming meeting of the American Academy of Dermatology.

LEO Pharma expects to file for regulatory approval of the treatment in the U.S. and Europe in 2011.

About Actinic Keratosis

Actinic keratosis (AK) is a common pre-cancerous skin condition caused by sun exposure, which can develop into skin cancers if left untreated. The number of AK patients is both large and rapidly growing, and AK is a serious health problem.

About LEO Pharma

Founded more than 100 years ago, LEO Pharma is an independent, research-based specialty pharmaceutical company committed to the discovery and development of novel drugs for patients within the areas of Dermatology and Critical Care Medicine. Wholly owned by The LEO Foundation, the company is headquartered in Ballerup, Denmark, outside of Copenhagen, and is represented in more than 90 countries worldwide.  Employees number more than 3,000, with 550 scientists and specialists working to develop new chemical entities.

With a strong portfolio of approved products and a robust pipeline of treatments in development for conditions including psoriasis, eczema and actinic (solar) keratosis, LEO Pharma is one of the leading dermatology companies in the U.S. and the world.  

For more information about LEO Pharma, visit www.leopharma.com.

SOURCE LEO Pharma

RELATED LINKS'/>"/>

SOURCE LEO Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
8. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Tenn., April 10 Leading RSV,investigator Dr. John DeVincenzo ... disease that causes bronchiolitis and pneumonia,according to the Centers ... the leading cause of hospitalization of infants in the ... in this age group., DeVincenzo is using the ...
... and drug development and clinical trial, ... BEDMINSTER, N.J., April 9, 2008 Clinsys ... research,organization (CRO), today introduced its Therapeutically-aligned Program,Strategists ... and execution,of clinical trials. The TPS teams ...
Cached Medicine Technology:RSV Researcher Makes Gains in Finding Treatments 2Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans 2Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans 3
(Date:9/1/2014)... regular family meals may help protect teens from the ... suggests. Online abuse can lead to depression, anxiety ... five adolescents experience cyberbullying," Frank Elgar, a professor at ... University in Montreal, said in a university news release. ... and abuse are difficult for parents and educators to ...
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. ... an experimental drug was more effective than standard treatment ... According to the study authors, the trial was ... new drug, dubbed LCZ696. In the trial, ... (Vasotec), either died or were hospitalized due to heart ...
(Date:9/1/2014)... 2014 Currently, scientists continue to ... for Alzheimer's disease (AD), which reflects their poor ... the diagnosis of the disease, especially in its ... diagnostic tests. In 2014, after decades that ... in the medicine world, there are still no ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market ... (the US, France, Italy, Germany, Spain and the UK), ... 2018. , The competitive landscape in the B-cell NHL ... the UK is poised to undergo a dramatic shift ... largest B-cell NHL indications, which includes Diffuse Large B-Cell ...
(Date:9/1/2014)... 2014 As well as having completed ... currently pursuing counselor certification in Louisiana. , ... CPI training program as well as the Counselor ... both personally and professionally. I am not only ... able to do so. As a Non Violent ...
Breaking Medicine News(10 mins):Health News:Family Meals May Defuse Cyberbullying's Impact, Study Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Narconon Louisiana Announces New Certifications For Staff 2
... Medical Corporation,(CRM:TSX-V) announced today that it has opened a ... Center is the Company,s first in the,state of New ... targeted for,expansion. The opening of this location represents the ... number of Centers to 14., According to the ...
... (IDF) BRIDGES translational research grant program will fund a ... for people at high-risk for getting type 2 diabetes ... develop a healthy lifestyle. , The National Hospital of ... Vietnam. Using diabetes risks questionnaires (1) , the investigators ...
... Gerson Lehrman Group, the world,s,leading marketplace for expertise, ... devoted to providing patients with the,medication information they ... personalized iGuard Risk Ratings, iGuard Safety Alerts,and a ... other registered,users who also want to get informed, ...
... is a chief reason that,patients seek medical attention; ... Physicians must be able to determine which opioid,treatment ... To make clinicians aware of the importance ... Current Clinical Practice and The,Journal of Family Practice: ...
... help breast cancer patients and menopausal women, study finds ... of a local anesthetic into the nerves of the ... long-term relief from hot flashes and sleep deprivation, a ... treatment for breast cancer, especially among women taking anti-estrogen ...
... INC. (Nasdaq:,PDEX) invites shareholders and investors to listen to ... financial results, and a discussion,of the outlook for the ... broadcast live over the Internet on,Thursday, May 15, 2008 ... by,visiting the Company,s website at http://www.pro-dex.com . Mark ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Treat Your Patients' Pain Effectively 2Health News:Hot Flashes Reduced by Neck Injection 2Health News:Hot Flashes Reduced by Neck Injection 3Health News:Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast 2
Indications For Usage: ,Used to automatically maintain a low intracuff pressure during long-term intubations....
Indications For Usage: ,Microlaryngeal surgery....
... Indications For Usage: ... ,The monitoring lumen is ... of tracheal gases especially end-tidal ... pressure. , Introducing medication. ...
... onset of VAP. (Valles J, Artigas A, ... subglottic secretions in preventing ventilator-associated pneumonia. Ann ... Auboyer C, Jospe R, et al: Prevention ... role of mechanical subglottic secretions drainage and ...
Medicine Products: